SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
about
Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism.The nuclear localization of MGF receptor in osteoblasts under mechanical stimulation.Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitroBronchial smooth muscle cells of asthmatics promote angiogenesis through elevated secretion of CXC-chemokines (ENA-78, GRO-α, and IL-8).A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling.Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer.Genetic and Pharmacologic Inhibition of the Chemokine Receptor CXCR2 Prevents Experimental Hypertension and Vascular Dysfunction.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.The complex world of oligodendroglial differentiation inhibitors.Pharmacological modulation of chemokine receptor function.Regulation of neutrophil trafficking from the bone marrow.Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor.What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.A common intracellular allosteric binding site for antagonists of the CXCR2 receptor.Angiostatin inhibits activation and migration of neutrophils.GPCR theme editorial.Synthesis, ADMET Properties, and Biological Evaluation of Benzothiazole Compounds Targeting Chemokine Receptor 2 (CXCR2).Molecular Approaches To Target GPCRs in Cancer Therapy.
P2860
Q33574947-61DD2226-B2DD-4502-B742-52B64D6A609FQ34323600-89FB5E6E-E30E-42FE-8945-6C58C549379CQ34394197-34A63A00-7FF3-461E-8F50-83CFEAA6C095Q34566429-B4F1A1F9-9EAA-4B5E-B7F9-02FAEBF479DBQ35067539-C4D9FF12-B865-4734-89A0-BFF0B88DD159Q35071967-CBF79E2F-640E-4FD4-AC06-16AC12BAD939Q35921720-8352F692-C0D5-4516-8ACC-CC1413960F66Q37375207-045E902D-0027-45FD-86F2-0D7285258EB0Q37432097-7237D728-6442-4710-85CA-6E2E4591925EQ37869047-6F202C3F-BA92-4055-B55A-3EC31E30483AQ37893687-2E8EBC19-6C94-4D97-981D-BEAC9767AD32Q37951866-6EE2CC01-38D3-4E1F-8771-DEDC783A19C9Q38195671-3237E159-2B4E-4D84-AEDD-597D8BAC890EQ38608720-20646F9D-F9C7-4960-B437-A2265D3F4CFDQ38680670-BF6AB6E9-A245-4E52-9FEA-732A3757AADCQ39321350-1588C9CC-B884-45B1-96B2-89DBD698285FQ39921218-C613693C-A2C0-468B-AC7B-2829C85A6C87Q42631171-200F4032-6E90-4AE9-A1C3-FAEF20F4CD56Q42951309-9CF296A2-3707-41BC-8FD2-5DEF370D40AEQ46442602-A6669E7B-6CD8-4342-B3BA-31B36358E001Q46850333-58B49979-EC39-476E-9C27-63D910D1E492
P2860
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
@en
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
@nl
type
label
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
@en
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
@nl
prefLabel
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
@en
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
@nl
P2093
P2860
P1476
SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2009.00182.X
P407
P577
2009-04-24T00:00:00Z